DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of claims 1-2, 5-6, 10-11, 26, and 34-40 with species election of SEQ ID NO:1 in the reply filed on June 26, 2026 is acknowledged.
Status of Claims
Claims 1-2, 5-6, 10-11, 26-28, 30, 34-42, 47-50, 54, 58-60, 63, 65-69, 72-74, 78, 80, and 83-84 are currently pending in the instant application. Claims 27-28, 30, 41-42, 47-50, 54, 58-60, 63, 65-69, 72-74, 78, 80, and 83-84 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Accordingly, claims 1-2, 5-6, 10-11, 26, and 34-40 are under examination on the merits in the instant application.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on August 17, 2023 has been considered by the examiner, except all NPL references. Note that the title of each of the cited NPL references must be included in the IDS.
Specification
1. The abstract of the disclosure is objected to because it contains the word “novel”, which is not descriptive of an invention. A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b).
2. The disclosure, see pages 48-49 and 53, is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Drawings
The drawings are objected to because FIGs. 9A-9D, contain sequence rule non-compliant subject matter. Appropriate correction is required as instructed below. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Nucleotide and/or Amino Acid Sequence Disclosures
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES
Items 1) and 2) provide general guidance related to requirements for sequence disclosures.
37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted:
In accordance with 37 CFR 1.821(c)(1) via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification as required by 37 CFR 1.823(b)(1) identifying:
the name of the ASCII text file;
ii) the date of creation; and
iii) the size of the ASCII text file in bytes;
In accordance with 37 CFR 1.821(c)(1) on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(8) and 37 CFR 1.823(b)(1) in a separate paragraph of the specification identifying:
the name of the ASCII text file;
the date of creation; and
the size of the ASCII text file in bytes;
In accordance with 37 CFR 1.821(c)(2) via the USPTO patent electronic filing system as a PDF file (not recommended); or
In accordance with 37 CFR 1.821(c)(3) on physical sheets of paper (not recommended).
When a “Sequence Listing” has been submitted as a PDF file as in 1(c) above (37 CFR 1.821(c)(2)) or on physical sheets of paper as in 1(d) above (37 CFR 1.821(c)(3)), 37 CFR 1.821(e)(1) requires a computer readable form (CRF) of the “Sequence Listing” in accordance with the requirements of 37 CFR 1.824.
If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via the USPTO patent electronic filing system as a PDF, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the PDF copy and the CRF copy (the ASCII text file copy) are identical.
If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or read-only optical disc, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the paper or read-only optical disc copy and the CRF are identical.
Specific deficiencies and the required response to this Office Action are as follows:
Specific deficiency – Amino acid sequences appearing in the drawings, see FIGs. 9A-9D, are not identified by sequence identifiers in accordance with 37 CFR 1.821(d). Sequence identifiers for nucleotide and/or amino acid sequences must appear either in the drawings or in the Brief Description of the Drawings.
Required response – Applicant must provide:
Replacement and annotated drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers;
AND/OR
A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125 inserting the required sequence identifiers into the Brief Description of the Drawings, consisting of:
A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
A copy of the amended specification without markings (clean version); and
A statement that the substitute specification contains no new matter.
Claim Rejections - Improper Markush Grouping
Claims 34-40 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination of process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP §706.03(y).
Note that “the phrase "Markush claim” means any claim that recites a list of alternatively useable species regardless of format.” See MPEP §2173.05(h).
The Markush grouping of SEQ ID NOs:1, 29-47, 49, and 96-97 is improper because the amino acid sequence alternatives defined by the Markush grouping do not share a single structural similarity. For instance, SEQ ID NO:1 elected by applicant shares only about 31% sequence identity with SEQ ID NO:29. As such, the alternatively recited sequences do not share a substantial structural feature and a common use flowing from the substantial structural feature.
To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternatives within a single claim in fact share a single structural similarity as well as a common use.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 11 and 30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 11 recites “a bulky group that can be detected by nanopore sequencing”. The term “bulky group” as recited is a relative term that is not clearly defined in the claim or in the specification, wherein the precise meaning of the “bulky group” may be different from one person to the next. As such, the metes and bounds of the aforementioned limitation cannot be clearly ascertained.
Claim 30 recites “adapter”. It is unclear what is referred to and meant by this word. Solely for examination purpose, “adapter” will be interpreted to mean “DNA adapter” disclosed at page 3 of the specification.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-2, 5-6, 10-11, 26, and 34-40 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The instant claims are drawn to a method that requires an hmC-CT, which helps production of a nucleic acid (e.g., mRNA, siRNA) with a modified cytosine when combined with a carbamoyl phosphate substrate, wherein the hmC-CT transfers the carbamoyl phosphate substrate onto a nucleotide triphosphate or a hydroxymethylcytosine in the nucleic acid.
The instant specification fails to clearly identify and disclose the precise identity (e.g., SEQ ID NO) of the “CT” that was actually used in the exemplified method. The specification merely discloses that the “CT open reading frame was cloned from a modified contig originally sequenced in sewage #2 containing both the thymidylate synthase and CT sequences into pET28b vector, expressed and purified the 63 kDa enzyme product.” See page 55. The specification, however, does not adequately describe/disclose which amino acid sequence (SEQ ID NO) corresponds to “the 63 kDa enzyme product”, which appears to be one and only species of the CT that is actually reduced to practice in the instant application. The concealment of the actual protein sequence of “the 63 kDa enzyme product” is far from adequately describing the identity of the CT that actually provided a modification of 5-hmC, and as such, it remains unknown and concealed whether applicant’s elected sequence of SEQ ID NO:1 corresponds to “the 63 kDa enzyme product”. Now, even if “the 63 kDa enzyme product” is expressly disclosed as being SEQ ID NO:1, the single CT amino acid sequence is not a representative number of species within the claimed genus of “hydroxymethylcytosine carbamoyltransferase (hmC-CT)”, which in and of itself was deemed previously unknown thus “novel” as evidenced by the instant specification’s disclosure at page 16 as following: “This novel enzyme family is here referred to as hmC-CT.” In light of the disclosed novelty pertaining to the claimed enzyme, the functionality provided by “the 63 kDa enzyme product” (presumed to be SEQ ID NO:1 for the sake of argument) cannot be extended to the variants of “at least 80% identity to” SEQ ID NO:1, let alone SEQ ID NO:29-47, 49, and 96-97, wherein SEQ ID NO:29 shares only about 31% sequence identity with SEQ ID NO:1. Even better, SEQ ID NO:96 is a mere 36 amino acid sequence comprising 31 of any naturally occurring amino acid residues, and SEQ ID NO:97 is only a 5 amino acid sequence comprising two of any naturally occurring amino acid residues. The instant specification is insufficient and inadequate in describing that the mere 5 amino acid sequence can function as an hmC-CT in the claimed method.
In the instant case, the instant specification does not provide any written description or guidance as to which amino acid residues of SEQ ID NO:1 or SEQ ID NO:29-47, 49, and 96-97 can be modified for the “at least 80% sequence identity”, wherein such modified sequence still retains the intended function of hmC-CT. In fact, a post-filing reference by Yang et al. (eLife, 2021, 10:e70021) suggests that “the novel 5-hydroxymethylcytosine (5hmC) carbamoyltransferase”, which is “the 63 kDa protein product”, might require “W408, G421, and R423”, which “may be important in defining the enzyme’s specificity toward cytosine derivatives”. See Figure 6; pages 11 and 13. This information pertaining to the three amino acid residues that impart the “specificity toward cytosine derivatives” was not known in the prior art, nor is it disclosed in the instant specification. That is, the instant specification does not provide any written description support in sufficient detail pertaining to which variants having amino acid residue substitutions have the required 5hmC-CT function. Note that the specificity and the content of the specification’s disclosure is inversely correlated with the level of knowledge and the level of predictability. Since there is no prior art knowledge, thus no predictability, pertaining to the claimed enzyme’s function, the instant specification must adequately describe the claimed subject matter and the claimed genus of structural elements in sufficient detail in order to satisfy the written description requirement. See MPEP §2163.
The specification also expressly discloses that hmC-CT “preferentially reacts with the hydroxyl group on 5-hmC on single stranded DNA, RNA or free nucleotide triphosphates in vitro to form a cmC” (emphasis added). See page 28. See also page 55 expressly disclosing that “our CT was active only on denatured single-stranded, but not double stranded DNA.” (emphasis added). The “cmC” (or 5-cmC; 5-carbamoyloxymethylcytosine) does not represent the nucleotide species modified from 5-hmC by the hmc-CT. Similarly, the single-stranded nucleic acid that is described to work with hmC-CT cannot represent the entire genus of the “nucleic acid”, “nucleic acid template”, or “nucleic acid product” encompassing both single-stranded and double-stranded structures including “siRNA” claimed in the instant case. It is also noted that the specification discloses, “No activity was shown for 5mdCTP or 5hmdUTP, indicating the CT is specific to 5-hmdCTP” (emphasis added). See page 55. As such, the instant specification expressly teaches and suggests that the “the 63 kDa enzyme product” is only “specific to 5-hmdCTP”, which is not representative of the entire genus of “nucleic acid” encompassing nucleotide triphosphates.
Regarding the reaction mixture as broadly claimed, the specification expressly discloses that “each component, namely carbamoyl phosphate, ATP, 5-hmdC from genomic T4gT DNA and the enzyme, was indispensable for the reaction.” See page 55. In fact, a post-filing reference by Yang et al. (Bio-protocol, 2022, 12:e4496, pages -14) discloses that the carbamoyltransferase enzyme assay reaction mixture requires additional reagents other than the expressly recited elements in the instant claims. See pages 3-4. As such, the reaction mixture disclosed in the instant specification’s experiments does not appear to describe that the elements recited in the instant claims are sufficient to practice the claimed methods.
In view of the foregoing, it is concluded that the instant specification fails to adequately describe the instantly claimed subject matter, especially, the identity of the 5hmC-CT, let alone the entire genus as instantly claimed in the manner to reasonably convey that the instant co-inventors had possession of the entire genus as of the filing date sought in the instant case.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANA H SHIN whose telephone number is (571)272-8008. The examiner can normally be reached Monday-Thursday: 8am - 6:30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, RAM SHUKLA can be reached at 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DANA H SHIN/Primary Examiner, Art Unit 1635